Advanta Ltd

Banjara Hills, India

Advanta Ltd

Banjara Hills, India
SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2017. Total revenue for the quarter was $25.5 million, a decrease of 12% from $29.0 million in the first quarter of 2016 and an increase of 2% from $25.1 million in the fourth quarter of 2016. GAAP net loss for the first quarter of 2017 was $17.2 million, compared with a GAAP net loss of $19.9 million for the first quarter of 2016. Non-GAAP net loss for the first quarter of 2017 was $9.6 million, compared with an $11.5 million non-GAAP net loss for the first quarter of 2016 (see accompanying table for reconciliation of GAAP and non-GAAP measures). “Our first quarter revenue was in line with our expectations. Importantly, we are making meaningful progress on our initiatives and working diligently to reshape our business. We are confident that the changes we are making position Fluidigm for sustainable long-term growth. In particular, we are excited about the enthusiasm for our broadening mass cytometry portfolio as evidenced by our new system placements and growth in consumables,” said Chris Linthwaite, President and CEO. “Also, we welcomed two new members, Nicolas Barthelemy and Carlos Paya, to our Board of Directors. Their deep industry knowledge and expertise will be instrumental in helping us accelerate key elements of our strategy. As we previously announced, John Young is retiring from the Board before the next annual meeting of stockholders. On behalf of the Board and the entire company, we thank John for his immeasurable contribution to Fluidigm,” continued Linthwaite. First Quarter 2017 Performance Total revenue of $25.5 million by category: Cash, cash equivalents, and investments as of March 31, 2017: Conference Call Information Fluidigm will host a conference call today, May 4, 2017, at 2:00 p.m. PT (5:00 p.m. ET). Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 91968572. Interested parties may access the live teleconference in the Investor Relations section of the company’s website at: http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on May 4, 2017. A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 91968572. The conference call will also be archived on the Fluidigm Investors page at: http://investors.fluidigm.com/. Statement Regarding Use of Non-GAAP Financial Information Fluidigm has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the first quarters of 2017 and 2016. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Our estimates of forward-looking non-GAAP operating expenses exclude estimates for stock-based compensation expense, depreciation and amortization; loss on disposal of property and equipment; future changes relating to developed and acquired technologies; other intangible assets; and income taxes, among other items, certain of which are presented in the table accompanying our earnings release. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our controls to predict. Accordingly, we cannot provide a quantitative reconciliation of our non-GAAP margins without unreasonable effort. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding planned strategic initiatives and expected timing and benefits of such initiatives, the planned uses and expected benefits to customers of recently-introduced products, plans to increase operational efficiency and improve financial discipline, and projected revenues, expenses and cash flows for the second quarter of 2017. Forward‑looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to introductions of new capital equipment products driving volatility in revenue from period to period, the future financial performance of Fluidigm product lines, particularly with respect to legacy instruments that may have contributed significant revenue in prior periods; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; Fluidigm research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm’s business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law. About Fluidigm Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm, the Fluidigm logo, Advanta, Biomark, and Helios are trademarks or registered trademarks of Fluidigm Corporation.


News Article | May 4, 2017
Site: globenewswire.com

SOUTH SAN FRANCISCO, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2017. Total revenue for the quarter was $25.5 million, a decrease of 12% from $29.0 million in the first quarter of 2016 and an increase of 2% from $25.1 million in the fourth quarter of 2016. GAAP net loss for the first quarter of 2017 was $17.2 million, compared with a GAAP net loss of $19.9 million for the first quarter of 2016. Non-GAAP net loss for the first quarter of 2017 was $9.6 million, compared with an $11.5 million non-GAAP net loss for the first quarter of 2016 (see accompanying table for reconciliation of GAAP and non-GAAP measures). “Our first quarter revenue was in line with our expectations. Importantly, we are making meaningful progress on our initiatives and working diligently to reshape our business. We are confident that the changes we are making position Fluidigm for sustainable long-term growth. In particular, we are excited about the enthusiasm for our broadening mass cytometry portfolio as evidenced by our new system placements and growth in consumables,” said Chris Linthwaite, President and CEO. “Also, we welcomed two new members, Nicolas Barthelemy and Carlos Paya, to our Board of Directors. Their deep industry knowledge and expertise will be instrumental in helping us accelerate key elements of our strategy. As we previously announced, John Young is retiring from the Board before the next annual meeting of stockholders. On behalf of the Board and the entire company, we thank John for his immeasurable contribution to Fluidigm,” continued Linthwaite. First Quarter 2017 Performance Total revenue of $25.5 million by category: Cash, cash equivalents, and investments as of March 31, 2017: Conference Call Information Fluidigm will host a conference call today, May 4, 2017, at 2:00 p.m. PT (5:00 p.m. ET). Individuals interested in listening to the conference call may do so by dialing (877) 556-5248 for domestic callers, or (720) 545-0029 for international callers. Please reference Conference ID 91968572. Interested parties may access the live teleconference in the Investor Relations section of the company’s website at: http://investors.fluidigm.com/events.cfm. The link will not be active until 1:45 p.m. PT (4:45 p.m. ET) on May 4, 2017. A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), Conference ID 91968572. The conference call will also be archived on the Fluidigm Investors page at: http://investors.fluidigm.com/. Statement Regarding Use of Non-GAAP Financial Information Fluidigm has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the first quarters of 2017 and 2016. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Our estimates of forward-looking non-GAAP operating expenses exclude estimates for stock-based compensation expense, depreciation and amortization; loss on disposal of property and equipment; future changes relating to developed and acquired technologies; other intangible assets; and income taxes, among other items, certain of which are presented in the table accompanying our earnings release. The time and amount of certain material items needed to estimate non-GAAP financial measures are inherently unpredictable or outside of our controls to predict. Accordingly, we cannot provide a quantitative reconciliation of our non-GAAP margins without unreasonable effort. Material changes to any of these items could have a significant effect on guidance and future GAAP results. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding planned strategic initiatives and expected timing and benefits of such initiatives, the planned uses and expected benefits to customers of recently-introduced products, plans to increase operational efficiency and improve financial discipline, and projected revenues, expenses and cash flows for the second quarter of 2017. Forward‑looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to introductions of new capital equipment products driving volatility in revenue from period to period, the future financial performance of Fluidigm product lines, particularly with respect to legacy instruments that may have contributed significant revenue in prior periods; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; Fluidigm research and development, sales, marketing, and distribution plans and capabilities; reduction in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm’s business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law. About Fluidigm Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm, the Fluidigm logo, Advanta, Biomark, and Helios are trademarks or registered trademarks of Fluidigm Corporation.


News Article | April 20, 2017
Site: globenewswire.com

   Mme Yannick Assouad est diplômée de l'Institut national des sciences appliquées et de l'Illinois Institute of Technology. En parallèle de ses responsabilités d'enseignante au Ciefop Paris, elle rejoint Thomson CSF (de 1986 à 1998), où elle assume la responsabilité du service thermique et mécanique, puis de la société Honeywell Aerospace (de 1998 à 2003) en qualité de directeur technique puis de directeur général, puis de présidente de Secan. En 2003, elle rejoint Zodiac Aerospace, où elle exerce le mandat de directeur général d'Intertechnique Services (de 2003 à 2008). En 2008, entrée au comité exécutif, elle crée la branche services du groupe, dont elle assume la direction jusqu'en 2010, date à laquelle elle prend la responsabilité de directeur général de la branche Aircraft Systems. En mai 2015, elle prend en charge la branche Cabin, nouvellement créée par Zodiac Aerospace. Depuis le 10 novembre 2016, elle est directeur général du groupe Latécoère. Mme Graziella Gavezotti est diplômée de l'Università di comunicazione e lingue (IULM) et de l'Université La Jolla [Rjeka]. Elle a effectué sa carrière au sein des groupes Jacques Borel, Gemeaz, Accor Services Italia et Edenred Italia. Jusqu'à mai 2012, elle a exercé la fonction de président-directeur général d'Edenred Italia. À partir de juillet 2012, elle garde la fonction de présidente du conseil d'administration en Italie et assume la fonction de Chief Operating Officer zone Europe du Sud (Italie, Espagne, Portugal, Turquie et Grèce). Elle est également membre du comité exécutif d'Edenred SA. M. Michael Pragnell est diplômé de l'université d'Oxford et de l'Insead. Après un poste au département international à la First National Bank of Chicago à New York, M. Pragnell occupe diverses fonctions au sein du groupe Courtaulds, de 1975 à 1995 : directeur général de National Plastics Ltd (1985-1986), directeur général d'International Paint plc (1986-1992) et directeur financier de Courtaulds plc (1992-1994), où il est nommé au conseil d'administration en 1990. De 1995 à 2000, il est directeur général de Zeneca Agrochemicals, membre du comité exécutif de Zeneca plc, devenue AstraZeneca plc, et nommé membre du conseil d'administration en 1997. De 2000 à 2007, il est directeur général fondateur et président du comité exécutif de Syngenta AG, dont il est aussi membre du conseil d'administration dès sa création. Par ailleurs, il a été administrateur au conseil de David S Smith plc de 1996 à 1999 et administrateur au conseil d'Advanta BV, une société néerlandaise. Il a été président de l'association CropLife International de 2002 à 2005 et président du conseil de Cancer Research UK de 2010 à 2016. En janvier 2017, M. Pragnell a été nommé commandant de l'Ordre de l'Empire britannique CBE. VINCI est un acteur mondial des métiers des concessions et de la construction, employant plus de 183 000 collaborateurs dans une centaine de pays. Sa mission est de concevoir, financer, construire et gérer des infrastructures et des équipements qui contribuent à l'amélioration de la vie quotidienne et à la mobilité de chacun. Parce que sa vision de la réussite est globale et va au-delà de ses résultats économiques, VINCI s'engage sur la performance environnementale, sociale et sociétale de ses activités. Parce que ses réalisations sont d'utilité publique, VINCI considère l'écoute et le dialogue avec l'ensemble des parties prenantes de ses projets comme une condition nécessaire à l'exercice de ses métiers. L'ambition de VINCI est ainsi de créer de la valeur à long terme pour ses clients, ses actionnaires, ses salariés, ses partenaires et pour la société en général.


News Article | April 20, 2017
Site: globenewswire.com

   Mme Yannick Assouad est diplômée de l'Institut national des sciences appliquées et de l'Illinois Institute of Technology. En parallèle de ses responsabilités d'enseignante au Ciefop Paris, elle rejoint Thomson CSF (de 1986 à 1998), où elle assume la responsabilité du service thermique et mécanique, puis de la société Honeywell Aerospace (de 1998 à 2003) en qualité de directeur technique puis de directeur général, puis de présidente de Secan. En 2003, elle rejoint Zodiac Aerospace, où elle exerce le mandat de directeur général d'Intertechnique Services (de 2003 à 2008). En 2008, entrée au comité exécutif, elle crée la branche services du groupe, dont elle assume la direction jusqu'en 2010, date à laquelle elle prend la responsabilité de directeur général de la branche Aircraft Systems. En mai 2015, elle prend en charge la branche Cabin, nouvellement créée par Zodiac Aerospace. Depuis le 10 novembre 2016, elle est directeur général du groupe Latécoère. Mme Graziella Gavezotti est diplômée de l'Università di comunicazione e lingue (IULM) et de l'Université La Jolla [Rjeka]. Elle a effectué sa carrière au sein des groupes Jacques Borel, Gemeaz, Accor Services Italia et Edenred Italia. Jusqu'à mai 2012, elle a exercé la fonction de président-directeur général d'Edenred Italia. À partir de juillet 2012, elle garde la fonction de présidente du conseil d'administration en Italie et assume la fonction de Chief Operating Officer zone Europe du Sud (Italie, Espagne, Portugal, Turquie et Grèce). Elle est également membre du comité exécutif d'Edenred SA. M. Michael Pragnell est diplômé de l'université d'Oxford et de l'Insead. Après un poste au département international à la First National Bank of Chicago à New York, M. Pragnell occupe diverses fonctions au sein du groupe Courtaulds, de 1975 à 1995 : directeur général de National Plastics Ltd (1985-1986), directeur général d'International Paint plc (1986-1992) et directeur financier de Courtaulds plc (1992-1994), où il est nommé au conseil d'administration en 1990. De 1995 à 2000, il est directeur général de Zeneca Agrochemicals, membre du comité exécutif de Zeneca plc, devenue AstraZeneca plc, et nommé membre du conseil d'administration en 1997. De 2000 à 2007, il est directeur général fondateur et président du comité exécutif de Syngenta AG, dont il est aussi membre du conseil d'administration dès sa création. Par ailleurs, il a été administrateur au conseil de David S Smith plc de 1996 à 1999 et administrateur au conseil d'Advanta BV, une société néerlandaise. Il a été président de l'association CropLife International de 2002 à 2005 et président du conseil de Cancer Research UK de 2010 à 2016. En janvier 2017, M. Pragnell a été nommé commandant de l'Ordre de l'Empire britannique CBE. VINCI est un acteur mondial des métiers des concessions et de la construction, employant plus de 183 000 collaborateurs dans une centaine de pays. Sa mission est de concevoir, financer, construire et gérer des infrastructures et des équipements qui contribuent à l'amélioration de la vie quotidienne et à la mobilité de chacun. Parce que sa vision de la réussite est globale et va au-delà de ses résultats économiques, VINCI s'engage sur la performance environnementale, sociale et sociétale de ses activités. Parce que ses réalisations sont d'utilité publique, VINCI considère l'écoute et le dialogue avec l'ensemble des parties prenantes de ses projets comme une condition nécessaire à l'exercice de ses métiers. L'ambition de VINCI est ainsi de créer de la valeur à long terme pour ses clients, ses actionnaires, ses salariés, ses partenaires et pour la société en général.


News Article | April 20, 2017
Site: globenewswire.com

   Mme Yannick Assouad est diplômée de l'Institut national des sciences appliquées et de l'Illinois Institute of Technology. En parallèle de ses responsabilités d'enseignante au Ciefop Paris, elle rejoint Thomson CSF (de 1986 à 1998), où elle assume la responsabilité du service thermique et mécanique, puis de la société Honeywell Aerospace (de 1998 à 2003) en qualité de directeur technique puis de directeur général, puis de présidente de Secan. En 2003, elle rejoint Zodiac Aerospace, où elle exerce le mandat de directeur général d'Intertechnique Services (de 2003 à 2008). En 2008, entrée au comité exécutif, elle crée la branche services du groupe, dont elle assume la direction jusqu'en 2010, date à laquelle elle prend la responsabilité de directeur général de la branche Aircraft Systems. En mai 2015, elle prend en charge la branche Cabin, nouvellement créée par Zodiac Aerospace. Depuis le 10 novembre 2016, elle est directeur général du groupe Latécoère. Mme Graziella Gavezotti est diplômée de l'Università di comunicazione e lingue (IULM) et de l'Université La Jolla [Rjeka]. Elle a effectué sa carrière au sein des groupes Jacques Borel, Gemeaz, Accor Services Italia et Edenred Italia. Jusqu'à mai 2012, elle a exercé la fonction de président-directeur général d'Edenred Italia. À partir de juillet 2012, elle garde la fonction de présidente du conseil d'administration en Italie et assume la fonction de Chief Operating Officer zone Europe du Sud (Italie, Espagne, Portugal, Turquie et Grèce). Elle est également membre du comité exécutif d'Edenred SA. M. Michael Pragnell est diplômé de l'université d'Oxford et de l'Insead. Après un poste au département international à la First National Bank of Chicago à New York, M. Pragnell occupe diverses fonctions au sein du groupe Courtaulds, de 1975 à 1995 : directeur général de National Plastics Ltd (1985-1986), directeur général d'International Paint plc (1986-1992) et directeur financier de Courtaulds plc (1992-1994), où il est nommé au conseil d'administration en 1990. De 1995 à 2000, il est directeur général de Zeneca Agrochemicals, membre du comité exécutif de Zeneca plc, devenue AstraZeneca plc, et nommé membre du conseil d'administration en 1997. De 2000 à 2007, il est directeur général fondateur et président du comité exécutif de Syngenta AG, dont il est aussi membre du conseil d'administration dès sa création. Par ailleurs, il a été administrateur au conseil de David S Smith plc de 1996 à 1999 et administrateur au conseil d'Advanta BV, une société néerlandaise. Il a été président de l'association CropLife International de 2002 à 2005 et président du conseil de Cancer Research UK de 2010 à 2016. En janvier 2017, M. Pragnell a été nommé commandant de l'Ordre de l'Empire britannique CBE. VINCI est un acteur mondial des métiers des concessions et de la construction, employant plus de 183 000 collaborateurs dans une centaine de pays. Sa mission est de concevoir, financer, construire et gérer des infrastructures et des équipements qui contribuent à l'amélioration de la vie quotidienne et à la mobilité de chacun. Parce que sa vision de la réussite est globale et va au-delà de ses résultats économiques, VINCI s'engage sur la performance environnementale, sociale et sociétale de ses activités. Parce que ses réalisations sont d'utilité publique, VINCI considère l'écoute et le dialogue avec l'ensemble des parties prenantes de ses projets comme une condition nécessaire à l'exercice de ses métiers. L'ambition de VINCI est ainsi de créer de la valeur à long terme pour ses clients, ses actionnaires, ses salariés, ses partenaires et pour la société en général.


Prior to joining Provident Bank, Kamin – who has more than three decades of experience in the financial services and information technology industries – was Executive Vice President, Chief Information Officer with Old National Bank, a $15 billion institution in Evansville, IN, where he was responsible for the bank's technology strategy and all technology-related activities.  While at Old National Bank, he successfully reoriented IT as a key business enabler, upgraded key infrastructure components, and successfully integrated seven acquisitions and numerous consolidations by instituting new methodologies and efficiencies.  Kamin also held senior leadership positions with Wells Fargo, Wachovia, and Advanta Corporation. "I am thrilled to join the talented team at Provident Bank.  They have a long tradition of providing the highest level of customer service while delivering innovative solutions to their clients.  Provident has a solid reputation for consistently delivering strong performance and growth.  I look forward to collaborating with my new colleagues to enhance the bank's offerings and to further engage existing clients and obtain new ones," said Kamin. Kamin received a bachelor's degree from Rutgers University.  He has a long history of service to non-profit organizations.  He served as the board chair of Youth First, board chair of the IT Alliance for the University of Southern Indiana, board member for National Public Radio local affiliate, and as a board member of the American Red Cross, where he served on the Strategic Planning Committee. About Provident Bank  Provident Bank, (www.provident.bank) a community-oriented bank offering "Commitment you can count on" since 1839, is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE: PFS), which reported assets of $9.51 billion as of March 31, 2017. With $6.53 billion in deposits, Provident Bank provides a comprehensive suite of financial products and services through its network of branches throughout northern and central New Jersey and eastern Pennsylvania. The Bank also provides fiduciary and wealth management services through its wholly owned subsidiary, Beacon Trust Company. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/john-kamin-joins-provident-bank-as-executive-vice-president-chief-information-officer-300460258.html


Waters D.L.E.,Southern Cross University of Australia | Subbaiyan G.K.,Indian Agricultural Research Institute | Mani E.,Advanta Ltd | Singh S.,Advanta Ltd | And 3 more authors.
Tropical Plant Biology | Year: 2015

The linear relationship between genetic distance and heterosis within maize heterotic groups has inspired efforts to predict heterosis using molecular markers in other species. In this study, three cytoplasmic male sterile and three restorer lines from a hybrid rice breeding program were crossed in all possible (9) combinations and the F1 offspring grown in replicated trials in three locations. Whole genome sequence analyses were used to identify hybrid pair genome-wide polymorphisms and the extent to which these polymorphisms were associated with heterosis estimated. The number of total hybrid pair SNP ranged from 150,823 to 331,876 and mid-parent heterosis from −13.6 % to 18.6 %. Hybrid pair total SNP, total INDEL, gene SNP and gene INDEL counts were generally correlated at the whole genome and chromosome level. There was a close correlation between chromosome SNP and INDEL frequencies while gene presence-absence analysis found little difference between cross combinations. The relationship between whole genome SNP and heterosis was best explained by a second order polynomial of negative sign, suggesting a positive heterotic response may be achieved by maintaining a balance between inbreeding and outbreeding depression, and that genome wide polymorphisms may have a role in predicting heterosis in rice. © 2015, Springer Science+Business Media New York.


Garg V.,Indian Agricultural Research Institute | Permar V.,Indian Agricultural Research Institute | Parkhi V.,Advanta Ltd. | Mani E.,Advanta Ltd. | And 3 more authors.
Journal of Plant Biochemistry and Biotechnology | Year: 2015

Tomato leaf curl disease (ToLCD) is associated with begomoviruses, with their generic names as Tomato leaf curl viruses (ToLCVs) and Tomato yellow leaf curl viruses (TYLCVs). ToLCVs exist both with mono/bipartite genomes, whereas TYLCVs carry monopartite genomes. For management of these viruses, three resistance loci Ty-1 to Ty-3 are being deployed, which provides different degree of resistance. These viruses encode a replication initiator protein (Rep), indispensible for virus replication. The conserved/divergent sequences of rep gene(s) were used to develop mono/bipartite virus specific PCR assay. The implications of distinguishing viruses with mono/bipartite genomes for using virus specific resistance loci through breeding have been discussed. © 2015, Society for Plant Biochemistry and Biotechnology.

Loading Advanta Ltd collaborators
Loading Advanta Ltd collaborators